Bank of New York Mellon Corp decreased its position in shares of Shire PLC (NASDAQ:SHPG) by 3.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 121,950 shares of the biopharmaceutical company’s stock after selling 4,498 shares during the quarter. Bank of New York Mellon Corp’s holdings in Shire PLC were worth $20,155,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Hartford Financial Management Inc. boosted its holdings in shares of Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 32 shares during the period. Thompson Davis & CO. Inc. boosted its holdings in shares of Shire PLC by 3.1% during the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 19 shares during the period. Stephens Inc. AR acquired a new position in shares of Shire PLC during the first quarter valued at $179,000. Quantbot Technologies LP acquired a new position in shares of Shire PLC during the first quarter valued at $182,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Shire PLC by 45.3% during the first quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 350 shares during the period. 19.13% of the stock is owned by institutional investors.

Shares of Shire PLC (NASDAQ:SHPG) opened at 158.46 on Friday. The firm has a market capitalization of $47.20 billion, a P/E ratio of 70.90 and a beta of 1.61. Shire PLC has a one year low of $139.36 and a one year high of $209.22. The firm has a 50-day moving average of $153.42 and a 200-day moving average of $168.82.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, equities analysts predict that Shire PLC will post $14.93 earnings per share for the current fiscal year.

The company also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio is 41.07%.

WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/17/bank-of-new-york-mellon-corp-has-20-16-million-stake-in-shire-plc-shpg.html.

Several equities analysts have recently issued reports on SHPG shares. Piper Jaffray Companies set a $159.00 price target on shares of Shire PLC and gave the company a “hold” rating in a report on Wednesday, July 26th. ValuEngine downgraded shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research downgraded shares of Shire PLC from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Sanford C. Bernstein downgraded shares of Shire PLC from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $209.22 to $161.09 in a report on Thursday, May 25th. Finally, BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $220.08.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.